Sign in to fuzzto save your conversations, follow your research and come back anytime.
Fermenta Biotech
FERMENTA
NSE
BSE
NSEBSESectorHealthcare
502.30
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Customer base expanded and domestic sales took lead, but earnings and key segment revenues cooled after a strong Q4 peak.
High-value clients grow from 2 in Q2 FY26 to 7 in Q4 FY26, strengthening the enterprise customer base.
Earnings per share fall from ₹7.49 in Q1 FY26 to ₹3.34 in Q1 FY27, reflecting compressed profitability.
India revenue share rises from 19% in Q1 FY26 to 47% in Q1 FY27, confirming a strong domestic sales shift.
Profit after tax drops from ₹22 Cr in Q1 FY26 to ₹9.5 Cr in Q1 FY27, highlighting margin pressure.
Major clients (>5% revenue) drop from 4 in Q2 FY26 to 2 in Q4 FY26, reducing dependency on single buyers.
Green Chemistry and Enzymes revenue plunges from ₹9.8 Cr in Q1 FY26 to ₹2.3 Cr in Q1 FY27, signaling sharp segment contraction.
Mid-tier clients expand from 41 in Q2 FY26 to 68 in Q4 FY26, building a wider revenue foundation.
Consolidated revenue cools from a peak of ₹551 Cr in Q4 FY26 to ₹121.8 Cr in Q1 FY27, showing seasonal normalization.
